EGFR-Mutated Lung Cancer Perspectives

In this video interview, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, discussed:

• how diagnosis or biomarker testing of EGFR-mutated lung cancer has evolved;
• treatment approaches for EGFR 19 deletions and EGFR L858R in small cell lung cancer;
• treatment variations for rarer mutations such as EGFR exon 20 insertions;
• the latest treatment options and treatments in the pipeline for EGFR-mutated lung cancer; and
• disparities that exist in the treatment.